Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from FDA

FDA moves to ease blood donor restrictions on gay men amid national shortage

The FDA is considering easing blood donor screening restrictions for gay and bisexual men.

Axios · Dec 2, 2022

New Alzheimer's drug shows modest slowing of early disease progression

Scientists are cautiously optimistic about the promise of an experimental drug shown to modestly slow the progression of Alzheimer's disease in some patients.

ABC News · Dec 1, 2022

Elon Musk's Neuralink demo promised miracles — but a neuroscientist says the tech is decades behind

The brain-computer interface technology touted by Neuralink has been around for several decades.

Inverse · Dec 1, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Elon Musk wants to put Neuralink implants in people’s brains within 6 months

Would you let Elon Musk’s company put a computer chip in your brain?

Evening Standard · Dec 1, 2022

Can health wearables help you sleep better? Here’s what your trackers are actually measuring

While most sleep trackers capture information on heart rate, oxygen levels, or movement, these metrics aren’t measuring sleep quality directly.

Inverse · Dec 1, 2022

FDA clears 1st fecal transplant treatment for gut infection

U.S. officials approved the first pharmaceutical-grade version of the fecal transplant procedures that doctors have increasingly used to treat a potentially life-threatening intestinal infection

The Independent UK · Nov 30, 2022

Mark Cuban’s prescription drug company in talks with hospitals to fill drug shortages

Mark Cuban’s prescription drug company, known for “cutting out the middle man,” is in conversations with hospitals around the nation to identify the most common drug shortages.

Tribune News Service · Nov 30, 2022

Read news from The Economist, FT, and more,
with one subscription

Data shows drug slowing Alzheimer’s but doubts over effect remain

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.

Al Jazeera · Nov 30, 2022

Laid off workers can now get a free month of ketamine assisted therapy services to help with their mental health

The free service from Field Trip Health is open to "anyone who's facing headwinds right now."

Fortune · Nov 30, 2022

3 Stocks That Still Have Room to Run

With the October inflation report showing signs of cooling and anticipations of a slowdown in interest rate hikes, the stock market looks poised to extend its recent rally. Hence, it could be wise to invest in fundamentally sound stocks Pfizer (PFE), Cisco Systems (CSCO), and Raytheon Technologies (RTX) that still…

StockNews.com · Nov 30, 2022

New Alzheimer's drug faces uncertain regulatory path

The FDA will soon decide whether to approve Eisai's experimental drug lecanemab.

Axios · Nov 30, 2022

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

WEKU · Nov 30, 2022

Drug slows Alzheimer's but can it make a real difference?

New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening

The Independent UK · Nov 30, 2022

Vet's lawsuit blaming antimalarial drug for psychosis tossed

A lawsuit against the maker of an anti-malarial drug blamed for causing psychotic and neurological damage in U.S. servicemembers has been thrown out

The Independent UK · Nov 30, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

Axios · Nov 29, 2022

Safety concerns hang over new Alzheimer's treatment

Two deaths linked to the drug may present a more complicated path to approval.

WEKU · Nov 29, 2022

The chase is on: Regulators are slowly cracking down on vapes aimed at teens

The advent of vaping revived nicotine addiction among young people after a dramatic decline. The FDA seems poised to at last yank some products aimed at teens from the market. Will it work?

StockNews.com · Nov 28, 2022

1 High-Dividend Stock to Add to Your Portfolio if You Haven’t Already

Amid prevalent COVID-19 cases, vaccine pioneer Pfizer (PFE) is significantly benefiting. Moreover, the company beat wall street expectations in the third quarter with a robust financial result and raised its revenue and EPS guidance for the year. Given its strong fundamentals, the stock could be a wise addition to your…

Bangkok Post · Nov 25, 2022

NVI plans to utilise local booster shots

The National Vaccine Institute (NVI) plans to use locally developed Covid-19 vaccines as booster shots when they are completed and approved by the Food and Drug Administration (FDA).

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com · Nov 24, 2022

3 Strong Buy Stocks to Continue to Hold Onto in 2023

As the Fed’s aggressive monetary policy resulted in slightly cooled inflation last month, investors are hopeful of smaller rate hikes ahead. However, since a recession is expected to hit the economy next year, we think fundamentally sound stocks Pfizer (PFE), Flowers Foods (FLO), and Xperi (XPER), which are rated Strong…

Reason · Nov 24, 2022

Come Next Thanksgiving, We Might Be Giving Thanks for Government-Approved, Lab-Grown Turkey

Regulators are beginning to smile on the sci-fi project of creating real meat products without the typical death and environmental destruction.

Reuters · Nov 24, 2022

Psychedelic mushrooms expand Jamaica tourism beyond sunshine and reggae

A new group of Jamaican resorts is promoting tourism that offers mystical experiences and stress relief through "magic mushrooms," as the Caribbean nation seeks to develop a niche industry in natural psychedelics.

The Guardian - US · Nov 23, 2022

Gene therapy at $3.5m a dose approved for US adults with hemophilia B

Hemgenix frees patients from repeated treatments but initial cost makes it most expensive medicine in the world

Tribune News Service · Nov 23, 2022

As STDs proliferate, companies rush to market at-home test kits. But are they reliable?

Among the more remarkable legacies of the COVID-19 pandemic is how quickly federal regulators, the health care industry and consumers moved to make at-home testing a reliable tool for managing a public health crisis.

The Independent UK · Nov 22, 2022

$3.5M gene therapy for hemophilia gets FDA approval

U.S. health regulators have approved the first gene therapy for hemophilia, a blood-clotting disorder with few treatment options

The Guardian - UK · Nov 22, 2022

‘This looks like the real deal’: are we inching closer to a treatment for Alzheimer’s?

After years of setbacks, dementia researchers are getting excited about a new antibody drug called lecanemab. No one expects it to stop cognitive decline, but even slowing it would be a breakthrough

1 … 236 237 238 239

Coverage From

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.